# US 2023/0057356 A1 · Enhancement of umbilical cord mesenchymal stem cell therapeutic activity by stimulators of t regulatory cells and/or cells expressing cd73

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0057356 A1
- Document ID: US20230057356A1
- Status: Published application
- Kind: A1
- Application number: 17/820,789
- Filed: 2022-08-18
- Published: 2023-02-23
- Earliest claimed: 2021-08-18
- Assignees: Therapeutic Solutions International, Inc.
- Applicants: Therapeutic Solutions International, Inc.
- Inventors: Thomas C. ICHIM; Famela RAMOS; James VELTMEYER; Timothy G. DIXON; Wais KAIHANI
- Web page: https://patentgrep.com/patent/US20230057356A1

## CPC

- A61K 35/51: Umbilical cord; Umbilical cord blood; Umbilical stem cells
- A61K 35/17: Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes (when activated by a specific antigen A61K39/00)
- A61K 35/28: Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
- A61K 38/2013: {IL-2}
- A61K 38/2086: {IL-13 to IL-16}
- C12N 5/0605: {Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly}
- C12N 5/0663: {Bone marrow mesenchymal stem cells (BM-MSC)}
- C12N 5/0667: {Adipose-derived stem cells [ADSC]; Adipose stromal stem cells}
- C12N 2500/98: Xeno-free medium and culture conditions
- C12N 2501/999: Small molecules not provided for elsewhere
- C12N 2502/115: Platelets, megakaryocytes
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Disclosed are means, compositions of matter and protocols useful for treatment of COVID-19 and/or other inflammatory pathologies through stimulation of T regulatory cells and/or T cells expressing CD73 using administration of umbilical cord derived mesenchymal stem cells such as JadiCells. In one embodiment dosage of JadiCells needed to treat a patient is determined by the increase of T regulatory cells and/or CD73 expressing cells that are increased in number and/or activity subsequent to a test dose of JadiCells. In another embodiment stimulators of T regulatory cells and/or CD73 expressing T cells are utilized together with JadiCells in order to augment therapeutic activity. In some embodiments administration of JadiCell is performed with low dose interleukin-2 as a treatment for COVID-19 or other inflammatory related pathologies.

## Claims

### Claim 1

A method of stimulating treating COVID-19 and/or an inflammatory condition in an adult comprising administration of a population of umbilical cord derived mesenchymal stem cells together with a stimulator of T regulatory cells and/or CD73 expressing T cells.

### Claim 2 (depends on 1)

The method of claim 1, wherein said T regulatory cells express FOXP3.

### Claim 3 (depends on 2)

The method of claim 2, wherein said ongoing inflammation is associated with increased levels of TNF-alpha as compared to an age-matched control.

### Claim 4 (depends on 2)

The method of claim 2, wherein said ongoing inflammation is associated with increased levels of IL-1 as compared to an age-matched control.

### Claim 5 (depends on 2)

The method of claim 2, wherein said ongoing inflammation is associated with increased levels of IL-6 as compared to an age-matched control.

### Claim 6 (depends on 2)

The method of claim 2, wherein said inflammation is associated with stimulation of toll like receptor (TLR) 1-9.

### Claim 7 (depends on 1)

The method of claim 1, wherein said umbilical cord mesenchymal stem cell is an isolated cell prepared by a process comprising: placing a subepithelial layer of a mammalian umbilical cord tissue in direct contact with a growth substrate; and culturing the subepithelial layer such that the isolated cell from the subepithelial layer is capable of self-renewal and culture expansion, wherein the isolated cell expresses at least three cell markers selected from the group consisting of CD29, CD73, CD90, CD166, SSEA4, CD9, CD44, CD146, or CD105, and wherein the isolated cell does not express NANOG and at least five cell markers selected from the group consisting of CD45, CD34, CD14, CD79, CD106, CD86, CD80, CD19, CD117, Stro-1, or HLA-DR.

### Claim 8 (depends on 7)

The isolated cell of claim 7, wherein the isolated cell produces exosomes expressing CD63, CD9, or CD63 and CD9.

### Claim 9 (depends on 7)

The isolated cell of claim 7, wherein culturing comprises culturing in a culture media that is free of animal components.

### Claim 10 (depends on 1)

The method of claim 1, wherein said stimulator of T regulatory cells and/or CD73 expressing T cells increases the numbers of said T regulatory cells and/or CD73 expressing T cells.

### Claim 11 (depends on 1)

The method of claim 1, wherein said stimulator of T regulatory cells and/or CD73 expressing T cells increases the activity of said T regulatory cells and/or CD73 expressing T cells.

### Claim 12 (depends on 11)

The method of claim 11, wherein said activity of said T regulatory cells and/or CD73 expressing T cells is quantified by expression of TGF-beta.

### Claim 13 (depends on 11)

The method of claim 11, wherein said activity of said T regulatory cells and/or CD73 expressing T cells is quantified by expression of interleukin 1 receptor antagonist.

### Claim 14 (depends on 11)

The method of claim 11, wherein said activity of said T regulatory cells and/or CD73 expressing T cells is quantified by expression of leukemia inhibitor factor.

### Claim 15 (depends on 11)

The method of claim 11, wherein said activity of said T regulatory cells and/or CD73 expressing T cells is quantified by expression of placenta induced growth factor.

### Claim 16 (depends on 11)

The method of claim 11, wherein said activity of said T regulatory cells and/or CD73 expressing T cells is quantified by expression of angiopoietin.

### Claim 17 (depends on 11)

The method of claim 11, wherein said activity of said T regulatory cells and/or CD73 expressing T cells is quantified by expression of platelet derived growth factor.

### Claim 18 (depends on 1)

The method of claim 1, wherein said stimulator of Treg and/or CD73 expressing T cells is low dose interleukin-2.

### Claim 19 (depends on 1)

The method of claim 1, wherein said stimulator of Treg and/or CD73 expressing T cells is low dose interleukin-13.

### Claim 20 (depends on 1)

The method of claim 1, wherein said stimulator of Treg and/or CD73 expressing T cells is low dose interleukin-15.
